Araclon Biotech, the Spanish biotech firm in which Grifols has a majority shareholding, have performed studies and made it possible to quantify the protein Aß-17 in the blood for the first time. The results show that it is the second most common amyloid beta in the blood (after Aß-40) and that its levels vary as Alzheimer’s disease progresses.
...